British Journal of Clinical Pharmacology · 1986 · 31 citations · 16 references
PharmacyPharmacokineticsPharmacologyBioavailabilityClinical PharmacologyDrug ClearanceCardiac MedicationsDrug DispositionHepatic BioavailabilityArterial Blood Pressure ControlDrug Formulation ComparisonHepatic Clearance DeclinePharmacokinetic ParametersPharmacokinetics Of Cardiovascular DrugsRelative Oral BioavailabilityTabletsVerapamil Therapy
Verapamil is a racemic mixture of two optical isomers, the (-)-form being the more active component. Recent studies indicate a rapid hepatic transformation of (-)-verapamil, which results in different concentration-effect relationships after oral and intravenous administration. In practice the important pharmacokinetic properties of verapamil are low bioavailability (20%), predominant elimination by metabolism (greater than 95%) and a relatively short half-life (t1/2, beta is 3-5 h). After repeated dosing, the rate of hepatic drug clearance seems to decrease. Slow release (SR) formulations of verapamil may offer certain therapeutic advantages during long-term treatment. A comparison of conventional (C) and SR tablets in a 1-week treatment of eight cardiac patients showed a relative bioavailability (AUCSR/AUCC) of 90 +/- 30%. More stable serum drug levels were maintained by 12-hourly administration of SR verapamil. A further study using a new 240 mg SR preparation in patients with arterial hypertension showed that even a single daily dose can be sufficient for adequate blood pressure control over 24 h.
16
Physiological disposition of verapamil in man
M Schomerus, B. Spiegelhalder, B. Stieren et al. · Cardiovascular Research · 1976 · 245 citations
B. Vogelgesang, H Echizen, Elke Schmidt et al. · British Journal of Clinical Pharmacology · 1984 · 180 citations · Full text
Verapamil disposition kinetics in chronic atrial fibrillation
Robert E. Kates, Deborah Keefe, Janice B. Schwartz et al. · Clinical Pharmacology & Therapeutics · 1981 · 118 citations